Welcome to our dedicated page for L A M Y SEC filings (Ticker: LMMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for L A M Y (LMMY) provides access to the company’s official regulatory disclosures, including current reports and notifications related to its evolving business. A key filing is the Form 8-K reporting L A M Y’s Plan and Agreement of Reorganization with Exousia AI, Inc., under which Exousia AI became a wholly owned subsidiary. In that document, the company explains that its board has adopted Exousia AI’s business plan, describing Exousia AI as a clinical stage biotechnology company focused on exosomes, with planned biotech, cosmeceutical, and nutraceutical divisions.
The 8-K also outlines the share issuance used to complete the acquisition and notes changes in management and control associated with the transaction. It provides a narrative of Exousia AI’s business, including its proprietary plant-based exosome manufacturing process and loading technology. This makes the filing a primary source for understanding L A M Y’s transition toward exosome-based biotechnology and its integration of Exousia AI’s operations.
Another important disclosure is the Form 12b-25 (NT 10-Q), in which L A M Y explains that it could not file a quarterly report on Form 10-Q by the prescribed deadline due to incomplete financial statements, auditor review, and management’s discussion and analysis. The notification indicates that the company expected to file within the extension period allowed by SEC rules and confirms that other required periodic reports had been filed over the preceding year.
On Stock Titan, these and other LMMY filings are organized in one place, with real-time updates as new documents are posted to EDGAR. AI-powered tools can help readers interpret lengthy narratives, highlight key sections about business combinations, exosome-related strategies, and reporting status, and make it easier to locate items such as current reports, late-filing notifications, and future annual or quarterly reports once filed.
L A M Y reported that it has completed the acquisition of Exousia Ai, Inc., a Florida clinical-stage biotechnology company developing plant-based exosome therapies, by issuing 62,223,000 shares of its common stock to Exousia Ai’s two shareholders. Following the closing on November 17, 2025, Exousia Ai became a wholly owned subsidiary and Exousia Pro Holding Management, LLC now owns 41,223,000 shares, representing about 58.89% of L A M Y’s 70,000,000 shares outstanding as of that date, resulting in a change of control and a shift in strategy to exosome-based biotech, cosmeceutical and nutraceutical products. Matthew Dwyer replaced Zhang Shengwu as sole officer and director, and the combined company highlights that Exousia Ai has received FDA Orphan Drug Designation for an exosome-based treatment for glioblastoma, while cautioning that it is early-stage, loss-making, under-capitalized and faces significant competition and financing, regulatory and penny‑stock market risks.
LAMY filed its quarterly report for the three months ended August 31, 2025, showing it remains a development-stage company with no operating revenue. The company reported a net loss of $31,814 for the quarter, compared with a net loss of $3,911 in the same period of 2024, driven mainly by professional fees, OTC market fees, and advertising expenses. As of August 31, 2025, LAMY reported total assets of $0 and total liabilities of $35,314, all current and largely due to related-party advances, resulting in a stockholders’ deficit of $35,314. The accumulated deficit since inception reached $63,584, and management states there is substantial doubt about the company’s ability to continue as a going concern. LAMY has 7,777,000 common shares outstanding and plans to rely on equity and/or debt financing and continued related-party support to fund operations, with no committed financing arrangements in place.
LAMY (LMMY)
Revenue was
The auditor issued a going concern opinion citing limited operations and an accumulated deficit of